Calamos Wealth Management LLC Has $1.61 Million Stake in AbbVie Inc. (NYSE:ABBV)

Calamos Wealth Management LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,060 shares of the company’s stock after acquiring an additional 208 shares during the quarter. Calamos Wealth Management LLC’s holdings in AbbVie were worth $1,610,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Patron Partners LLC increased its position in AbbVie by 9.4% during the 4th quarter. Patron Partners LLC now owns 7,208 shares of the company’s stock valued at $1,281,000 after buying an additional 618 shares in the last quarter. Columbus Macro LLC lifted its position in AbbVie by 221.0% during the 4th quarter. Columbus Macro LLC now owns 42,881 shares of the company’s stock worth $7,620,000 after acquiring an additional 29,524 shares during the period. Alliance Wealth Advisors LLC UT increased its stake in shares of AbbVie by 2.7% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 18,040 shares of the company’s stock valued at $3,206,000 after purchasing an additional 480 shares in the last quarter. Vantage Point Financial LLC purchased a new position in AbbVie in the 4th quarter worth approximately $205,000. Finally, Fourpath Capital Management LLC grew its position in AbbVie by 13.4% in the 4th quarter. Fourpath Capital Management LLC now owns 7,426 shares of the company’s stock valued at $1,320,000 after acquiring an additional 876 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 3.4 %

NYSE:ABBV opened at $190.20 on Tuesday. The company’s 50-day simple moving average is $176.57 and its 200-day simple moving average is $185.13. The stock has a market capitalization of $336.12 billion, a P/E ratio of 79.25, a P/E/G ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period in the previous year, the business posted $2.79 earnings per share. On average, equities analysts anticipate that AbbVie Inc. will post 12.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABBV. Citigroup upped their price target on shares of AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday. Argus upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. UBS Group upped their target price on AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a report on Monday. Piper Sandler Companies restated an “overweight” rating and set a $220.00 price target on shares of AbbVie in a report on Tuesday, December 17th. Finally, BMO Capital Markets increased their target price on AbbVie from $208.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.